{"id":"glucophage-tablets-and-victoza","safety":{"commonSideEffects":[{"rate":"20-40","effect":"Gastrointestinal disturbance (nausea, diarrhea, vomiting)"},{"rate":"5-15","effect":"Hypoglycemia"},{"rate":"10-15","effect":"Headache"},{"rate":"<1","effect":"Lactic acidosis (metformin, rare)"}]},"_chembl":{"chemblId":"CHEMBL1628401","moleculeType":"Small molecule","molecularWeight":"657.81"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Metformin is a biguanide that decreases hepatic gluconeogenesis and enhances peripheral glucose uptake, primarily through AMPK activation. Liraglutide is a GLP-1 receptor agonist that enhances glucose-dependent insulin secretion, suppresses glucagon secretion, and slows gastric emptying. Together, they provide complementary glucose-lowering effects for type 2 diabetes management.","oneSentence":"Glucophage (metformin) reduces hepatic glucose production and improves insulin sensitivity, while Victoza (liraglutide) stimulates insulin secretion and reduces glucagon in response to blood glucose levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:47:10.108Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT07244003","phase":"PHASE4","title":"Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control","status":"RECRUITING","sponsor":"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","startDate":"2025-03-29","conditions":"T2DM (Type 2 Diabetes Mellitus)","enrollment":430},{"nctId":"NCT02879409","phase":"NA","title":"HbA1c Variability in Type II Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Cornell Medical College in Qatar","startDate":"2016-11","conditions":"Diabetes Mellitus Type 2","enrollment":150},{"nctId":"NCT06449235","phase":"PHASE4","title":"Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh","status":"NOT_YET_RECRUITING","sponsor":"Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders","startDate":"2024-09","conditions":"Type2diabetes","enrollment":938},{"nctId":"NCT02960659","phase":"PHASE1, PHASE2","title":"Title: Therapeutic Targets in African-American Youth With Type 2 Diabetes","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2017-05-09","conditions":"Type 2 Diabetes","enrollment":24},{"nctId":"NCT01779362","phase":"PHASE3","title":"RISE Adult Medication Study","status":"COMPLETED","sponsor":"RISE Study Group","startDate":"2013-04","conditions":"Prediabetes, Type 2 Diabetes","enrollment":267},{"nctId":"NCT02787551","phase":"PHASE3","title":"Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-07-06","conditions":"Type 2 Diabetes Mellitus","enrollment":514},{"nctId":"NCT01541215","phase":"PHASE3","title":"Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2012-11-13","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":135},{"nctId":"NCT03235050","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-08-02","conditions":"Diabetes Mellitus, Type 2","enrollment":834},{"nctId":"NCT02205528","phase":"PHASE2","title":"A Study of Once-Daily NNC0090-2746 in Participants With Type 2 Diabetes Inadequately Controlled With Metformin","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2014-08-18","conditions":"Diabetes, Diabetes Mellitus Type 2","enrollment":108},{"nctId":"NCT04373967","phase":"PHASE3","title":"Study to Assess the Efficacy and Safety of Liraglutide in the Treatment of Type 2 Diabetes","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2020-04-29","conditions":"Type 2 Diabetes","enrollment":424},{"nctId":"NCT01966978","phase":"PHASE4","title":"The Effect of Simple Basal Insulin Titration, Metformin Plus Liraglutide for Type 2 Diabetes With Very Elevated HbA1c - The SIMPLE Study","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2014-11","conditions":"Diabetes Mellitus, Type 2, Diabetes","enrollment":157},{"nctId":"NCT01907854","phase":"PHASE4","title":"Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and Metformin","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2013-12-02","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":407},{"nctId":"NCT01725126","phase":"PHASE2","title":"To Investigate the Safety, Tolerability and Pharmacodynamics of GSK2890457 in Healthy Volunteers and Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-02-10","conditions":"Obesity","enrollment":53},{"nctId":"NCT01917656","phase":"PHASE4","title":"Efficacy and Safety of Liraglutide Versus Sulphonylurea Both in Combination With Metformin During Ramadan in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2014-01-09","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":343},{"nctId":"NCT01296412","phase":"PHASE3","title":"Comparison of Two Treatment Regimens (Sitagliptin Versus Liraglutide) on Participants Who Failed to Achieve Good Glucose Control on Metformin Alone (MK-0431-403)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-03-11","conditions":"Diabetes Mellitus, Type 2","enrollment":653},{"nctId":"NCT00856986","phase":"PHASE3","title":"The Effect of Insulin Detemir in Combination With Liraglutide and Metformin Compared to Liraglutide and Metformin in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2009-03","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":987},{"nctId":"NCT00700817","phase":"PHASE3","title":"The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2008-06","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":665},{"nctId":"NCT00614120","phase":"PHASE3","title":"Effect of Liraglutide or Glimepiride Added to Metformin on Blood Glucose Control in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2008-01","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":929},{"nctId":"NCT00318461","phase":"PHASE3","title":"To Compare the Effect of Liraglutide When Given Together With Metformin With the Effect of Metformin Given Alone and With the Effect of Glimepiride and Metformin Given Together","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2006-05","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":1091},{"nctId":"NCT01518101","phase":"PHASE4","title":"Vildagliptin Versus Liraglutide - Patient Preference After Receiving Both Medications","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-01","conditions":"Type 2 Diabetes","enrollment":62},{"nctId":"NCT03034941","phase":"PHASE4","title":"Short Term Weight Loss With Liraglutide and Metformin in Infertile Obese PCOS Patients","status":"COMPLETED","sponsor":"University Medical Centre Ljubljana","startDate":"2014-04","conditions":"Obesity, PCOS","enrollment":35},{"nctId":"NCT01785043","phase":"PHASE4","title":"Differences in Endothelial Function Amongst Sitagliptin and Liraglutide Users","status":"COMPLETED","sponsor":"Anna Cruceta","startDate":"2013-03","conditions":"DIABETES Mellitus Type 2 Not Well Controlled","enrollment":13},{"nctId":"NCT02483299","phase":"PHASE4","title":"Liraglutide as Add on Therapy on Metformin in Women With Polycystic Ovary Syndrome","status":"COMPLETED","sponsor":"University Medical Centre Ljubljana","startDate":"2014-01","conditions":"PCOS, Obesity","enrollment":40},{"nctId":"NCT01399645","phase":"PHASE2","title":"Study of Liraglutide Versus Insulin on Liver Fat Fraction in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Centre hospitalier de l'Université de Montréal (CHUM)","startDate":"2011-05","conditions":"Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, Type 2 Diabetes","enrollment":35},{"nctId":"NCT02187250","phase":"PHASE4","title":"PDE-4 Inhibitor Roflumilast and GLP-1 Agonist Liraglutide in Polycystic Ovary Syndrome","status":"COMPLETED","sponsor":"University Medical Centre Ljubljana","startDate":"2014-03","conditions":"PCOS, Obesity","enrollment":45},{"nctId":"NCT01911468","phase":"PHASE4","title":"Polycystic Ovary Syndrome and Liraglutide as Add-on Therapy on Metformin","status":"COMPLETED","sponsor":"University Medical Centre Ljubljana","startDate":"2011-11","conditions":"PCOS, Obesity","enrollment":36},{"nctId":"NCT01899430","phase":"PHASE4","title":"Polycystic Ovary Syndrome and Liraglutide","status":"COMPLETED","sponsor":"University Medical Centre Ljubljana","startDate":"2011-11","conditions":"PCOS, Obesity","enrollment":32},{"nctId":"NCT01593137","phase":"PHASE4","title":"A Long-term Trial to Compare the Effects of Liraglutide and Sulphonylurea (Glimepiride) Both in Combination With Metformin on Clinical, Endothelial and Image Markers of Cardiovascular Risk in Patients With Type 2 Diabetes","status":"WITHDRAWN","sponsor":"Fundación Fernández-Cruz","startDate":"2012-05","conditions":"Type 2 Diabetes","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Glucophage tablets and Victoza 6 mg/ml solution for injection in pre-filled pen"],"phase":"marketed","status":"active","brandName":"Glucophage tablets and Victoza","genericName":"Glucophage tablets and Victoza","companyName":"University Medical Centre Ljubljana","companyId":"university-medical-centre-ljubljana","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Glucophage (metformin) reduces hepatic glucose production and improves insulin sensitivity, while Victoza (liraglutide) stimulates insulin secretion and reduces glucagon in response to blood glucose levels. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}